These will be followed by novel products targeting people with diabetes and weight problems containing ingredients that are not yet marketed, but are backed by clinical data, Thorne chief executive Paul Jacobson told NutraIngredients-USA.
Longer-term, Indena would develop new, clinically-validated botanical ingredients for supplements to be manufactured and marketed to licensed health-care practitioners exclusively by Thorne in one or more specific therapeutic areas, said Jacobson
While Indena already supplied Thorne with a “fairly large number of products”, the new deal was “more expansive”, said Jacobson. “There are new products coming and some exclusivity on some existing products”.
Cancer supportive care, glucose control, weight management
He added: “There will be 4-6 products for oncology supportive care for our venture with [Swiss pharma company] Helsinn. There are a few for glucose and weight management that are not marketed yet, but have efficacy data.
“The partnership adds products that will have more scientific proof of efficacy, and strengthens our oncology supportive care and diabetes and weight offerings. It also adds additional research in very specific therapeutic areas.”
Click here to read more about the deal with Indena.